STADA and SBP Group have launched a strategic biosimilars partnership beginning with a proposed Keytruda biosimilar and providing a framework for up to three additional programmes.

Merck has secured exclusive worldwide rights to SciBrunch Therapeutics' preclinical KRAS G12D inhibitor SPR2015 in an oncology licensing transaction worth up to $2.13 billion.

The FDA has approved Teva's DEGEVMA as a biosimilar to Xgeva across all reference-product indications, expanding competition in denosumab treatment.

The FDA has approved Lyrfigtu for adults with previously treated FGFR2-altered cholangiocarcinoma, adding a new targeted therapy for this molecularly defined group of bile duct cancers.

The FDA has granted final approval to Lantheus' Bravnetsa for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours.

Boehringer Ingelheim and Envisagenics have entered a multi-year oncology collaboration worth more than $1 billion to discover therapeutic targets created by alternative RNA splicing.

Novartis has secured exclusive worldwide rights to an undisclosed preclinical radioligand therapy from BoomRay Pharma in a licensing agreement worth up to $900 million.

AbbVie and Iambic have entered a multi-year collaboration to use artificial intelligence and computational drug discovery across immunology, neuroscience and oncology.

Grünenthal has agreed to acquire Bayer's established oncology medicine Stivarga in a transaction worth up to €375 million.

The FDA has approved Inluriyo in combination with Verzenio for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer following progression on endocrine therapy.

Telix Pharmaceuticals has agreed to acquire ITM in a major radiopharmaceutical transaction valued at $1.65 billion upfront, with up to a further $700 million linked to regulatory and commercial milestones.

Escugen Biotechnology and Sovran Biosciences have expanded their oncology collaboration with a co-development agreement for a pan-tumour bispecific antibody-drug conjugate.

The FDA has approved shorter monitoring requirements following the first two doses of Amgen's Imdelltra, reducing observation time from 22–24 hours to 6–8 hours.

The FDA has expanded the approved use of Ameluz with red-light photodynamic therapy to include treatment of superficial basal cell carcinoma in adults.

The FDA has approved Curium's Bexlutry as the first radioligand equivalent to Lutathera for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours.

GSK has acquired full global rights to Chimagen Biosciences' trispecific T-cell engager programme for multiple myeloma in a transaction worth up to $750 million.

Cardiff Oncology and Nerviano have resolved their licensing dispute and amended the global onvansertib licence agreement, updating exclusivity, economics and termination provisions.

Medicus Pharma has secured exclusive worldwide rights to Pfizer's CD228-targeted antibody-drug conjugate PF-08046031 in an oncology licensing agreement potentially worth more than $1 billion.

Lupin has received Indian marketing approval for a pegfilgrastim biosimilar used to reduce the risk of chemotherapy-induced neutropenia.

Novacyt has commercially launched the IVDR-certified Yourgene Insight DPYD assay across regulated European markets to support identification of patients at increased risk of severe fluoropyrimidine toxicity.